Relmada Therapeutics (RLMD) Tops Q1 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.87), $0.03 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance